

Pediatric Cancer in Idaho, 1995-2005

Although relatively rare in comparison with cancer in older adults, cancer is the second leading cause of death in persons aged 1-14 years. The epidemiology of cancer among children differs markedly from that of adults, both in the patterns of anatomic sites involved and the predominant histologic types. Most notably, the tumors diagnosed in children frequently involve the hematopoietic and central nervous systems or are of mesenchymal origin. In contrast, malignancies of epithelial tissues, which are predominant in adults, are uncommon in children. Similar to adult cancers, the etiology of many childhood cancers remains unclear.

The Cancer Data Registry of Idaho receives several requests per year from physicians and others for data on pediatric cancer incidence for the state of Idaho. This report describes the incidence of pediatric cancers in Idaho, with comparisons to data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program.¹ SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 26 percent of the US population and is considered the standard for quality among cancer registries around the world.

METHODS

The data analyzed for this report include cancers diagnosed between 1995 and 2005 among Idaho residents less than 20 years of age. Cases were grouped according to the International Classification of Childhood Cancer (ICCC) based on site and morphology coded according to ICD-O-3.²

A total of 783 cases of malignant cancer were diagnosed among Idaho resident children under the age of 20 between 1995 and 2005. It was not possible to assign a group code of the ICCC system to 3 cases. Health District was assigned from county of residence at time of diagnosis. All rates presented were calculated per million population, and are averages for the period 1995 through 2005 (rates per million, rather than per 100,000, are commonly used for pediatric cancers). Age-adjustment was performed using the direct method to the 2000 U.S. standard population. All cancer incidence and survival statistics were calculated using SEER*Stat.³

RESULTS

A total of 780 cases that met the study criteria were diagnosed among Idaho residents aged less than 20 years between 1995 and 2005, yielding an overall age-adjusted rate of 171.7 cases per million population. In comparison, the SEER rate for Whites was 171.6 cases per million population. The distribution of pediatric cancers by ICCC grouping was very similar for Idaho and SEER Regions. Idaho's pediatric rate of astrocytomas was about 35% higher than the rate for SEER Whites ($p < .05$). For no other ICCC grouping was there a statistically significant difference between the pediatric cancer incidence rates in Idaho and SEER Regions.

About 80% of children aged less than 20 years diagnosed with malignant cancer survived at least 5 years after their diagnosis, both in Idaho and SEER Regions. Neither overall nor for any ICCC major classification category was there a statistically significant difference in 5-year relative survival between Idaho and SEER cases.

Pediatric cancer incidence has increased at a rate of about 0.8% per year in Idaho from 1970 to 2005. This parallels the long term increase observed in SEER Regions from 1973 to 2004 of about 0.8% per year.

Health District 6 had a statistically significantly lower ($p < .05$) rate of other malignant epithelial neoplasms and melanomas (ICCC major classification category XI) than the State of Idaho. For no other ICCC major classification category was there a statistically significant difference between any health district and the State of Idaho.

CONCLUSIONS

These data demonstrate strong similarity in pediatric cancer incidence and survival patterns between Idaho and SEER Regions. Compared with cancer in adults, there is little evidence for geographic variability in pediatric cancer incidence. Based upon the results in this report, the Cancer Data Registry of Idaho will continue to monitor pediatric astrocytoma incidence statewide.

Pediatric Cancer in Idaho and SEER Regions (Ages 0-19)

Site/Type of Cancer	Idaho 1995-2005			SEER13 1995-2004		
	Rate	Cases	Pop	Rate	Cases	Pop
All Sites Combined	171.7	780	4,507,283	171.6	14,222	82,780,003
I Leukemias, myeloproliferative & myelodysplastic diseases	42.3	190	4,507,283	47.0	3,951	82,780,003
I(a) Lymphoid leukemias	30.2	135	4,507,283	36.8	3,103	82,780,003
I(b) Acute myeloid leukemias	8.3	38	4,507,283	8.2	679	82,780,003
I(c) Chronic myeloproliferative diseases	1.8	8	4,507,283	0.9	72	82,780,003
I(d) Myelodysplastic syndrome and other myeloproliferative	0.2	1	4,507,283	0.2	21	82,780,003
I(e) Unspecified and other specified leukemias	1.8	8	4,507,283	0.9	76	82,780,003
II Lymphomas and reticuloendothelial neoplasms	25.0	115	4,507,283	24.8	2,008	82,780,003
II(a) Hodgkin lymphomas	12.7	59	4,507,283	13.1	1,056	82,780,003
II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma)	8.3	38	4,507,283	8.1	658	82,780,003
II(c) Burkitt lymphoma	2.3	10	4,507,283	2.5	203	82,780,003
II(d) Miscellaneous lymphoreticular neoplasms	1.6	7	4,507,283	0.7	57	82,780,003
II(e) Unspecified lymphomas	0.2	1	4,507,283	0.4	34	82,780,003
III CNS and misc intracranial and intraspinal neoplasms	36.2	162	4,507,283	29.6	2,472	82,780,003
III(a) Ependymomas and choroid plexus tumor	1.3	6	4,507,283	2.6	216	82,780,003
III(b) Astrocytomas	19.6	88	4,507,283	14.4	1,198	82,780,003
III(c) Intracranial and intraspinal embryonal tumors	8.1	36	4,507,283	7.1	595	82,780,003
III(d) Other gliomas	6.4	29	4,507,283	4.9	403	82,780,003
III(e) Other specified intracranial/intraspinal neoplasms	0.7	3	4,507,283	0.4	33	82,780,003
III(f) Unspecified intracranial and intraspinal neoplasms	0.0	0	4,507,283	0.3	27	82,780,003
IV Neuroblastoma and other peripheral nervous cell tumors	5.6	25	4,507,283	7.9	685	82,780,003
IV(a) Neuroblastoma and ganglioneuroblastoma	5.4	24	4,507,283	7.6	662	82,780,003
IV(b) Other peripheral nervous cell tumors	0.2	1	4,507,283	0.3	23	82,780,003
V Retinoblastoma	2.9	13	4,507,283	3.2	283	82,780,003
VI Renal tumors	5.9	26	4,507,283	6.1	525	82,780,003
VI(a) Nephroblastoma and other nonepithelial renal tumors	5.6	25	4,507,283	5.7	491	82,780,003
VI(b) Renal carcinomas	0.2	1	4,507,283	0.4	34	82,780,003
VI(c) Unspecified malignant renal tumors	0.0	0	4,507,283	0.0	0	82,780,003
VII Hepatic tumors	1.6	7	4,507,283	2.0	173	82,780,003
VII(a) Hepatoblastoma	0.9	4	4,507,283	1.5	132	82,780,003
VII(b) Hepatic carcinomas	0.7	3	4,507,283	0.5	39	82,780,003
VII(c) Unspecified malignant hepatic tumors	0.0	0	4,507,283	0.0	2	82,780,003
VIII Malignant bone tumors	10.4	48	4,507,283	8.6	698	82,780,003
VIII(a) Osteosarcomas	5.8	27	4,507,283	4.8	386	82,780,003
VIII(b) Chondrosarcomas	0.4	2	4,507,283	0.4	32	82,780,003
VIII(c) Ewing tumor and related sarcomas of bone	3.3	15	4,507,283	2.9	235	82,780,003
VIII(d) Other specified malignant bone tumors	0.2	1	4,507,283	0.5	37	82,780,003
VIII(e) Unspecified malignant bone tumors	0.6	3	4,507,283	0.1	8	82,780,003
IX Soft tissue and other extraosseous sarcomas	11.7	53	4,507,283	11.9	983	82,780,003
IX(a) Rhabdomyosarcomas	5.4	24	4,507,283	4.6	387	82,780,003
IX(b) Fibrosarcomas, peripheral nerve & other fibrous	0.9	4	4,507,283	1.3	107	82,780,003
IX(c) Kaposi sarcoma	0.0	0	4,507,283	0.0	2	82,780,003
IX(d) Other specified soft tissue sarcomas	3.5	16	4,507,283	4.8	391	82,780,003
IX(e) Unspecified soft tissue sarcomas	2.0	9	4,507,283	1.2	96	82,780,003
X Germ cell & trophoblastic tumors & neoplasms of gonads	11.1	52	4,507,283	12.5	1,010	82,780,003
X(a) Intracranial & intraspinal germ cell tumors	1.1	5	4,507,283	1.8	148	82,780,003
X(b) Extracranial & extragonadal germ cell tumors	1.1	5	4,507,283	1.4	123	82,780,003
X(c) Malignant gonadal germ cell tumors	7.9	37	4,507,283	8.6	693	82,780,003
X(d) Gonadal carcinomas	1.0	5	4,507,283	0.4	33	82,780,003
X(e) Other and unspecified malignant gonadal tumors	0.0	0	4,507,283	0.2	13	82,780,003


Pediatric Cancer in Idaho and SEER Regions (Ages 0-19) - continued

Site/Type of Cancer	Idaho 1995-2005			SEER13 1995-2004		
	Rate	Cases	Pop	Rate	Cases	Pop
XI Other malignant epithelial neoplasms and melanomas	18.1	85	4,507,283	17.3	1,386	82,780,003
XI(a) Adrenocortical carcinomas	0.0	0	4,507,283	0.3	27	82,780,003
XI(b) Thyroid carcinomas	6.4	30	4,507,283	6.4	515	82,780,003
XI(c) Nasopharyngeal carcinomas	0.4	2	4,507,283	0.3	24	82,780,003
XI(d) Malignant melanomas	7.4	35	4,507,283	6.3	508	82,780,003
XI(e) Skin carcinomas	0.0	0	4,507,283	0.1	8	82,780,003
XI(f) Other and unspecified carcinomas	3.9	18	4,507,283	3.8	304	82,780,003
XII Other and unspecified malignant neoplasms	0.9	4	4,507,283	0.6	48	82,780,003
XII(a) Other specified malignant tumors	0.7	3	4,507,283	0.3	27	82,780,003
XII(b) Other unspecified malignant tumors	0.2	1	4,507,283	0.3	21	82,780,003
Not classified by ICCC or in situ	0.6	3	4,507,283	0.6	47	82,780,003

Rates are per 1,000,000 and age-adjusted to the 2000 U.S. standard.

SEER data are for White race. Cases and rates are for malignant behavior only.

Statistical Note: Rates based upon 10 or fewer cases (numerator) should be interpreted with caution.




Five Year Relative Cancer Survival by Major ICCC Classification Category

Site/Type of Cancer	Idaho 1995-2005			SEER13 1995-2004		
	Cases	% Survival	95% CI	Cases	% Survival	95% CI
All Sites Combined	752	79.5%	76.2% - 82.8%	13,809	79.7%	78.9% - 80.5%
I Leukemias, myeloproliferative & myelodysplastic diseases	187	79.6%	73.3% - 85.9%	3,852	77.0%	75.4% - 78.6%
II Lymphomas and reticuloendothelial neoplasms	111	88.2%	81.7% - 94.7%	1,979	89.4%	87.8% - 91.0%
III CNS and misc intracranial and intraspinal neoplasms	154	73.7%	65.9% - 81.5%	2,400	74.4%	72.4% - 76.4%
IV Neuroblastoma and other peripheral nervous cell tumors	25	69.2%	49.8% - 88.6%	673	70.5%	66.4% - 74.6%
V Retinoblastoma	11	100.0%	100.0% - 100.0%	276	98.4%	96.4% - 100.0%
VI Renal tumors	26	87.0%	73.1% - 100.0%	513	88.6%	85.5% - 91.7%
VII Hepatic tumors	7	n/a	n/a - n/a	166	51.5%	42.5% - 60.5%
VIII Malignant bone tumors	42	58.3%	40.3% - 76.3%	670	64.4%	60.1% - 68.7%
IX Soft tissue and other extraosseous sarcomas	51	82.9%	70.6% - 95.2%	933	70.0%	66.7% - 73.3%
X Germ cell & trophoblastic tumors & neoplasms of gonads	52	85.3%	74.9% - 95.7%	987	90.9%	88.7% - 93.1%
XI Other malignant epithelial neoplasms and melanomas	82	87.2%	77.6% - 96.8%	1,314	90.0%	88.0% - 92.0%
XII Other and unspecified malignant neoplasms	4	35.7%	0.0% - 90.8%	46	67.8%	53.1% - 82.5%

Pediatric Cancer in Idaho and SEER Regions (Ages 0-19)

Year of Diagnosis	Idaho 1994-2004			SEER13 1995-2004		
	Rate	Cases	Pop	Rate	Cases	Pop
Total	171.7	780	4,507,283	174.6	14,467	82,780,003
1995	151.0	59	389,310	164.6	1,334	8,067,418
1996	173.6	69	395,663	167.3	1,369	8,156,211
1997	126.7	51	400,866	165.4	1,360	8,216,504
1998	178.2	73	406,767	177.0	1,466	8,273,535
1999	164.5	69	411,481	167.5	1,391	8,317,117
2000	146.5	61	414,559	178.2	1,484	8,338,245
2001	203.2	85	416,592	179.9	1,503	8,352,912
2002	195.1	82	417,490	187.1	1,561	8,344,686
2003	209.0	88	417,567	165.9	1,386	8,348,812
2004	176.9	75	418,312	192.1	1,613	8,364,563
2005	160.4	68	418,676			

Rates are per 1,000,000 and age-adjusted to the 2000 US Std Million standard.



Pediatric Cancer in Idaho (Ages 0-19) by Health District, Major Classification Categories

Site/Type of Cancer	Health District 1			Health District 2			Health District 3		
	Rate	95% CI	Cases	Rate	95% CI	Cases	Rate	95% CI	Cases
All Sites Combined	173.9	140.9 - 212.2	97	122.4	85.6 - 169.7	37	175.9	146.3 - 209.7	124
I Leukemias, myeloproliferative & myelodysplastic diseases	38.8	24.0 - 59.4	21	24.4	9.7 - 50.7	7	49.3	34.3 - 68.5	35
II Lymphomas and reticuloendothelial neoplasms	22.9	12.2 - 39.2	13	30.8	14.6 - 58.0	10	25.6	15.2 - 40.4	18
III CNS and misc intracranial and intraspinal neoplasms	27.4	15.3 - 45.2	15	17.8	5.7 - 41.9	5	39.8	26.4 - 57.5	28
IV Neuroblastoma and other peripheral nervous cell tumors	7.8	2.1 - 19.6	4	11.7	2.4 - 33.6	3	2.6	0.3 - 9.7	2
V Retinoblastoma	1.9	0.0 - 10.4	1	0.0	0.0 - 13.3	0	2.7	0.3 - 9.9	2
VI Renal tumors	5.6	1.1 - 16.3	3	0.0	0.0 - 13.3	0	12.5	5.7 - 23.7	9
VII Hepatic tumors	0.0	0.0 - 6.7	0	0.0	0.0 - 13.3	0	0.0	0.0 - 5.2	0
VIII Malignant bone tumors	12.1	4.8 - 25.1	7	13.1	3.5 - 34.4	4	4.4	0.9 - 12.7	3
IX Soft tissue and other extraosseous sarcomas	10.6	3.9 - 23.2	6	3.9	0.1 - 21.0	1	7.2	2.3 - 16.7	5
X Germ cell & trophoblastic tumors & neoplasms of gonads	16.3	7.4 - 31.1	9	9.2	1.8 - 28.2	3	10.1	4.1 - 20.7	7
XI Other malignant epithelial neoplasms and melanomas	28.8	16.8 - 46.3	17	11.3	3.0 - 30.8	4	20.4	11.1 - 34.1	14
XII Other and unspecified malignant neoplasms	1.7	0.0 - 9.7	1	0.0	0.0 - 13.3	0	1.5	0.0 - 8.0	1

Site/Type of Cancer	Health District 4			Health District 5			Health District 6			Health District 7		
	Rate	95% CI	Cases	Rate	95% CI	Cases	Rate	95% CI	Cases	Rate	95% CI	Cases
All Sites Combined	185.5	161.2 - 212.4	209	170.3	138.3 - 207.6	98	153.4	123.8 - 187.9	93	185.4	153.6 - 221.9	121
I Leukemias...	44.0	32.7 - 58.1	50	39.1	24.5 - 59.1	22	38.6	24.5 - 57.9	23	50.7	34.6 - 71.7	32
II Lymphomas...	20.6	13.0 - 30.8	23	34.4	21.0 - 53.2	20	21.0	11.2 - 36.0	13	24.2	14.0 - 39.1	17
III CNS and...	39.9	29.1 - 53.3	45	28.1	16.1 - 45.7	16	36.2	22.7 - 54.8	22	49.2	33.3 - 70.0	31
IV Neuroblastoma...	4.3	1.4 - 10.1	5	3.6	0.4 - 12.9	2	10.0	3.7 - 21.8	6	4.9	1.0 - 14.3	3
V Retinoblastoma	5.0	1.8 - 11.0	6	3.6	0.4 - 12.8	2	0.0	0.0 - 6.1	0	3.3	0.4 - 11.7	2
VI Renal tumors	6.9	3.0 - 13.7	8	1.8	0.0 - 9.9	1	3.5	0.4 - 12.3	2	5.1	1.0 - 14.6	3
VII Hepatic tumors	3.5	0.9 - 8.9	4	3.5	0.4 - 12.6	2	0.0	0.0 - 6.1	0	1.8	0.0 - 9.3	1
VIII Malignant bone tumors	11.8	6.3 - 20.1	13	15.1	6.9 - 28.8	9	11.7	4.7 - 24.0	7	7.7	2.5 - 18.0	5
IX Soft tissue...	15.1	8.8 - 24.1	17	10.4	3.8 - 22.7	6	15.0	6.9 - 28.5	9	13.9	6.3 - 26.4	9
X Germ cell...	13.6	7.6 - 22.3	15	6.8	1.8 - 17.4	4	14.3	6.5 - 27.2	9	7.0	2.2 - 16.7	5
XI Other malig epithelial...	20.9	13.2 - 31.3	23	22.1	11.8 - 37.9	13	3.1	0.4 - 11.6	2	16.1	8.3 - 28.6	12
XII Other/unspecified...	0.0	0.0 - 3.2	0	1.8	0.0 - 10.0	1	0.0	0.0 - 6.1	0	1.7	0.0 - 9.1	1

Rates are per 1,000,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard;

Confidence intervals (CIs) are 95% for rates.

Statistical Note: Rates based upon 10 or fewer cases (numerator) should be interpreted with caution.

Appendix A

Site/histology recode based on International Classification of Childhood Cancer, Third edition (ICCC-3) based on ICD-O-3¹

Site Group	ICD-O-3 Histology (Type)	ICD-O-2/3 Site	Recode
I Leukemias, myeloproliferative diseases, and myelodysplastic diseases			
(a) Lymphoid leukemias	9820, 9823, 9826, 9827, 9831-9837, 9940, 9948	C000-C809	011
(b) Acute myeloid leukemias	9840, 9861, 9866, 9867, 9870-9874, 9891, 9895-9897, 9910, 9920, 9931	C000-C809	012
(c) Chronic myeloproliferative diseases	9863, 9875, 9876, 9950, 9960-9964	C000-C809	013
(d) Myelodysplastic syndrome and other myeloproliferative diseases	9945, 9946, 9975, 9980, 9982-9987, 9989	C000-C809	014
(e) Unspecified and other specified leukemias	9800, 9801, 9805, 9860, 9930	C000-C809	015
II Lymphomas and reticuloendothelial neoplasms			
(a) Hodgkin lymphomas	9650-9655, 9659, 9661-9665, 9667	C000-C809	021
(b) Non-Hodgkin lymphomas (except Burkitt lymphoma)	9591, 9670, 9671, 9673, 9675, 9678-9680, 9684, 9689-9691, 9695, 9698-9702, 9705, 9708, 9709, 9714, 9716-9719, 9727-9729, 9731-9734, 9760-9762, 9764-9769, 9970	C000-C809	022
(c) Burkitt lymphoma	9687	C000-C809	023
(d) Miscellaneous lymphoreticular neoplasms	9740-9742, 9750, 9754-9758	C000-C809	024
(e) Unspecified lymphomas	9590, 9596	C000-C809	025
III CNS and miscellaneous intracranial and intraspinal neoplasms			
(a) Ependymomas and choroid plexus tumor	9383, 9390-9394	C000-C809	031
(b) Astrocytomas	9380	C723	032
	9384, 9400-9411, 9420, 9421-9424, 9440-9442	C000-C809	032
(c) Intracranial and intraspinal embryonal tumors	9470-9474, 9480, 9508	C000-C809	033
	9501-9504	C700-C729	033
(d) Other gliomas	9380	C700-C722, C724-C729, C751, C753	034
	9381, 9382, 9430, 9444, 9450, 9451, 9460	C000-C809	034

(e) Other specified intracranial and intraspinal neoplasms	8270-8281, 8300, 9350-9352, 9360-9362, 9412, 9413, 9492, 9493, 9505-9507, 9530-9539, 9582	C000-C809	035
(f) Unspecified intracranial and intraspinal neoplasms	8000-8005	C700-C729, C751-C753	036
IV Neuroblastoma and other peripheral nervous cell tumors			
(a) Neuroblastoma and ganglioneuroblastoma	9490, 9500	C000-C809	041
(b) Other peripheral nervous cell tumors	8680-8683, 8690-8693, 8700, 9520-9523	C000-C809	042
	9501-9504	C000-C699, C739-C768, C809	042
V Retinoblastoma	9510-9514	C000-C809	050
VI Renal tumors			
(a) Nephroblastoma and other nonepithelial renal tumors	8959, 8960, 8964-8967	C000-C809	061
	8963, 9364	C649	061
(b) Renal carcinomas	8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8143, 8155, 8190-8201, 8210, 8211, 8221-8231, 8240, 8241, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8401, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8576	C649	062
	8311, 8312, 8316-8319, 8361	C000-C809	062
(c) Unspecified malignant renal tumors	8000-8005	C649	063
VII Hepatic tumors			
(a) Hepatoblastoma	8970	C000-C809	071
(b) Hepatic carcinomas	8010-8041, 8050-8075, 8082, 8120-8122, 8140, 8141, 8143, 8155, 8190-8201, 8210, 8211, 8230, 8231, 8240, 8241, 8244-8246, 8260-8264, 8310, 8320, 8323, 8401, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8576	C220, C221	072
	8160-8180	C000-C809	072
(c) Unspecified malignant hepatic tumors	8000-8005	C220, C221	073
VIII Malignant bone tumors			
(a) Osteosarcomas	9180-9187, 9191-9195, 9200	C400-C419, C760-C768, C809	081
(b) Chondrosarcomas	9210, 9220, 9240	C400-C419, C760-C768, C809	082
	9221, 9230, 9241-9243	C000-C809	082
(c) Ewing tumor and related sarcomas of bone	9260	C400-C419, C760-C768, C809	083
	9363-9365	C400-C419	083

(d) Other specified malignant bone tumors	8810, 8811, 8823, 8830	C400-C419	084
	8812, 9250, 9261, 9262, 9270-9275, 9280-9282, 9290, 9300-9302, 9310-9312, 9320-9322, 9330, 9340-9342, 9370-9372	C000-C809	084
(e) Unspecified malignant bone tumors	8000-8005, 8800, 8801, 8803-8805	C400-C419	085
IX Soft tissue and other extraosseous sarcomas			
(a) Rhabdomyosarcomas	8900-8905, 8910, 8912, 8920, 8991	C000-C809	091
(b) Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms	8810, 8811, 8813-8815, 8821, 8823, 8834-8835	C000-C399, C440-C768, C809	092
	8820, 8822, 8824-8827, 9150, 9160, 9491, 9540-9571, 9580	C000-C809	092
(c) Kaposi sarcoma	9140	C000-C809	093
(d) Other specified soft tissue sarcomas	8587, 8710-8713, 8806, 8831-8833, 8836, 8840-8842, 8850-8858, 8860-8862, 8870, 8880, 8881, 8890-8898, 8921, 8982, 8990, 9040-9044, 9120-9125, 9130-9133, 9135, 9136, 9141, 9142, 9161, 9170-9175, 9231, 9251, 9252, 9373, 9581	C000-C809	094
	8830	C000-C399, C440-C768, C809	094
	8963	C000-C639, C659-C699, C739-C768, C809	094
	9180, 9210, 9220, 9240	C490-C499	094
	9260	C000-C399, C470-C759	094
	9364	C000-C399, C470-C639, C659-C699, C739-C768, C809	094
	9365	C000-C399, C470-C639, C659-C768, C809	094
(e) Unspecified soft tissue sarcomas	8800-8805	C000-C399, C440-C768, C809	095
X Germ cell tumors, trophoblastic tumors, and neoplasms of gonads			
(a) Intracranial and intraspinal germ cell tumors	9060-9065, 9070-9072, 9080-9085, 9100, 9101	C700-C729, C751-C753	101
(b) Malignant extracranial and extragonadal germ cell tumors	9060-9065, 9070-9072, 9080-9085, 9100-9105	C000-C559, C570-C619, C630-C699, C739-C750, C754-C768, C809	102
(c) Malignant gonadal germ cell tumors	9060-9065, 9070-9073, 9080-9085, 9090, 9091, 9100, 9101	C569, C620-C629	103
(d) Gonadal carcinomas	8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8143, 8190-8201,	C569, C620-C629	104

	8210, 8211, 8221-8241, 8244-8246, 8260-8263, 8290, 8310, 8313, 8320, 8323, 8380-8384, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8573, 9000, 9014, 9015		
	8441-8444, 8450, 8451, 8460-8473	C000-C809	104
(e) Other and unspecified malignant gonadal tumors	8590-8671	C000-C809	105
	8000-8005	C569, C620-C629	105
XI Other malignant epithelial neoplasms and malignant melanomas			
(a) Adrenocortical carcinomas	8370-8375	C000-C809	111
(b) Thyroid carcinomas	8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8190, 8200, 8201, 8211, 8230, 8231, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8430, 8440, 8480, 8481, 8510, 8560-8573	C739	112
	8330-8337, 8340-8347, 8350	C000-C809	112
(c) Nasopharyngeal carcinomas	8010-8041, 8050-8075, 8082, 8083, 8120-8122, 8130-8141, 8190, 8200, 8201, 8211, 8230, 8231, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8430, 8440, 8480, 8481, 8500-8576	C110-C119	113
(d) Malignant melanomas	8720-8780, 8790	C000-C809	114
(e) Skin carcinomas	8010-8041, 8050-8075, 8078, 8082, 8090-8110, 8140, 8143, 8147, 8190, 8200, 8240, 8246, 8247, 8260, 8310, 8320, 8323, 8390-8420, 8430, 8480, 8542, 8560, 8570-8573, 8940, 8941	C440-C449	115
(f) Other and unspecified carcinomas	8010-8084, 8120-8157, 8190-8264, 8290, 8310, 8313-8315, 8320-8325, 8360, 8380-8384, 8430-8440, 8452-8454, 8480-8586, 8588-8589, 8940, 8941, 8983, 9000, 9010-9016, 9020, 9030	C000-C109, C129-C218, C239-C399, C480-C488, C500-C559, C570-C619, C630-C639, C659-C729, C750-C768, C809	116
XII Other and unspecified malignant neoplasms			
(a) Other specified malignant tumors	8930-8936, 8950, 8951, 8971-8981, 9050-9055, 9110	C000-C809	121
	9363	C000-C399, C470-C759	121
(b) Other unspecified malignant tumors	8000-8005	C000-C218, C239-C399, C420-C559, C570-C619, C630-C639, C659-C699, C739-C750, C754-C809	122
Not Classified by ICC or in situ			999

References

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Limited-Use, Nov 2006 Sub (1992-2004) - Linked To County Attributes - Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
 2. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. *Cancer*, 2005;103:1457-67.
 3. Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 6.3.5.
-